2019
DOI: 10.1186/s12934-019-1076-2
|View full text |Cite
|
Sign up to set email alerts
|

Large-scale production of tauroursodeoxycholic acid products through fermentation optimization of engineered Escherichia coli cell factory

Abstract: BackgroundBear bile powder is a valuable medicinal material characterized by high content of tauroursodeoxycholic acid (TUDCA) at a certain ratio to taurochenodeoxycholic acid (TCDCA). We had created an engineered E. coli harboring two-step bidirectional oxidative and reductive enzyme-catalyzing pathway that could rapidly convert TCDCA to TUDCA at a specific percentage in shake flasks.ResultsWe reported here the large-scale production of TUDCA containing products by balancing the bidirectional reactions throug… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
24
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 16 publications
(24 citation statements)
references
References 44 publications
0
24
0
Order By: Relevance
“…In light of the available knowledge, it may be stated that although a lot is already known about the biological effects of TUDCA/UDCA in a variety of different cell types and disease models, it is still a very attractive compound to investigate as a potential multifunctional pharmacological agent. This seems to be confirmed by constant progress in design and synthesis of novel and more active analogues as well as synthetic derivatives of these molecules [196][197][198]. Thus, despite certain limitations in utilizing TUDCA as a ready-to-use therapeutic approach in a wide variety of human morbidities, contemporary investigations bring high hopes for the development of efficient TUDCA-based therapeutics in the future.…”
Section: Therapeutic Perspectives and Limitationsmentioning
confidence: 94%
“…In light of the available knowledge, it may be stated that although a lot is already known about the biological effects of TUDCA/UDCA in a variety of different cell types and disease models, it is still a very attractive compound to investigate as a potential multifunctional pharmacological agent. This seems to be confirmed by constant progress in design and synthesis of novel and more active analogues as well as synthetic derivatives of these molecules [196][197][198]. Thus, despite certain limitations in utilizing TUDCA as a ready-to-use therapeutic approach in a wide variety of human morbidities, contemporary investigations bring high hopes for the development of efficient TUDCA-based therapeutics in the future.…”
Section: Therapeutic Perspectives and Limitationsmentioning
confidence: 94%
“…Our study using E. coli as host cell demonstrated that all the four combinations of 7α-HSDH and 7β-HSDH, α1β1, α1β2, α2β1, and α2β2, have the capability to convert TCDCA to TUDCA, and fermentation condition has important effect on the conversion e ciency (Shi et al 2017;Xu et al 2019). Applying the given conditions, we found that CEN-α2β2 is the best combination for TUDCA biotransformation (Fig.…”
Section: Discussionmentioning
confidence: 75%
“…In vitro biotransformation condition optimization Based on the catalytic properties of the original 7α-HSDH and 7β-HSDH, and our ndings on E. coli (Shi et al 2017;Xu et al 2019), substrate concentration, pH value, temperature, and the fermentation time also have in uence on the substrate conversion e ciency. Meanwhile, 7α-HSDH and 7β-HSDH are NAD(P) +dependent enzymes.…”
Section: In Vitro Biotransformation Of Tudcamentioning
confidence: 84%
See 2 more Smart Citations